Inhibrx Biosciences Publishes Presentation on Ozekibart Phase 2 Chondrosarcoma Results
Bitget2026/10/29 19:36- Inhibrx Biosciences published a presentation on secondary efficacy results from its randomized Phase 2 ChonDRAgon study of ozekibart in advanced conventional chondrosarcoma.
- Median progression-free survival by independent review reached 5.52 months with ozekibart versus 2.66 months with placebo.
- Disease control rates were 54% with ozekibart versus 27.5% with placebo.
- Ozekibart delayed deterioration in pain and physical functioning compared with placebo.
- Grade 3 or higher treatment-emergent adverse events occurred in 39% of ozekibart patients versus 25.4% receiving placebo.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Elon Musk: SpaceX (SPCX.US) Q4 revenue is expected to increase by approximately 70% quarter-on-quarter, with government contract income share falling below 10%
Elon Musk stated on Friday that SpaceX (SPCX.US) will continue to reduce its dependence on U.S. government procurement contracts.
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Turtle Creek Asset Management Reports Sale of $347,850 in Jeld-Wen Common Shares
Crypto prices
More
